AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25643127
Drug: Onabotulinumtoxin A
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Onabotulinumtoxin A injections
Trial: 12803593
Drug: Lignocaine 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine 5% ointment (n = 50)
Trial: 1310916
Drug: Steady-state mild
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steady-state mild hypothermia (rectal temperature 33.9 +/- 0.7 degrees C)
Trial: 6147293
Drug: Somatostatin at
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin at a dose of 250 micrograms/h in saline (n = 12)
Trial: 24531238
Drug: Early rehabilitation
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early rehabilitation interventions including consultation with a rehabilitation physician, pain management, physiotherapy, psychological treatment, and further specialist referrals
Trial: 7636819
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (5 minutes application)
Trial: 1968739
Drug: Xamoterol (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xamoterol (0.15 mg/Kg intravenous injection)
Trial: 1968739
Drug: Xamoterol during
RxNorm normalized name: Xamoterol
DrugBank: Xamoterol (DB13781)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xamoterol during dobutamine infusion
Trial: 655186
Drug: Hydrochlorothiazide, 50
RxNorm normalized name: HydroCHLOROthiazide, 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide, 50 mg daily (with 10 mg of amiloride or 50 mg of spironolactone)
Trial: 655186
Drug: Acebutolol, 2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol, 2000 mg for 48 hours (in-hospital evaluation)
Trial: 655186
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (acebutolol and diuretics)
Trial: 17724529
Drug: Pantoprazol 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazol 40 mg/day for 12 weeks
Trial: 16986228
Drug: Amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg once daily
Trial: 24432037
Drug: Avanafil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avanafil (200 mg) 0.5 hours before NTG
Trial: 24432037
Drug: Sildenafil (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (100 mg) 0.5 hours before NTG
Trial: 24432037
Drug: Sildenafil (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (100 mg) 1 hour before NTG
Trial: 20810219
Drug: Estrogen‐containing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen‐containing hormone therapy
Trial: 12688320
Drug: High-dose methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methylprednisolone (HDMP) in Group B1
Trial: 12688320
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose steroids in Group A2 and A3
Trial: 9042991
Drug: Placebo, subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, subcutaneous injection 5 min before ingestion of a test meal
Trial: 1607272
Drug: Quinidine bisulphate
RxNorm normalized name: quinidine bisulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine bisulphate 500 mg from Teva
Trial: 1607272
Drug: Quinidine bisulphate
RxNorm normalized name: quinidine bisulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine bisulphate 250 mg from Teva
Trial: 1607272
Drug: Short-acting quinidine
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting quinidine sulphate 200 mg
Trial: 15709892
Drug: Fluoxetine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine + Cognitive Behavioural Therapy (CBT)
Trial: 21878034
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy (CBT) alone
Trial: 15709892
Drug: No Fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Fluoxetine (placebo)
Trial: 10485771
Drug: Intramuscular rocuronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular rocuronium (1 mg/kg for infants, 1.8 mg/kg for children)
Trial: 10485771
Drug: Intravenous rocuronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous rocuronium (0.45 mg/kg)
Trial: 10485771
Drug: Intramuscular rocuronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular rocuronium
Trial: 8938532
Drug: Ribavirin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin (1000 or 1200 mg/day for 24 weeks)
Trial: 25210879
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of GLP‐1 (0.9 pmol/kg/min)
Trial: 17512607
Drug: Olanzapine-Fluoxetine Combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine-Fluoxetine Combination (OFC) (6/25, 6/50, or 12/50 mg/day)
Trial: 8103703
Drug: Cetirizine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (15 mg single dose)
Trial: 8542164
Drug: Placebo (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (7 days treatment)
Trial: 1673975
Drug: Cetirizine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (single dose)
Trial: 1673975
Drug: Cetirizine (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (7 days treatment)
Trial: 7284885
Drug: 6 ml
RxNorm normalized name: ethanol 0.6 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 ml of bupivacaine 0.5 per cent
Trial: 21793047
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy (CPT) via video teleconferencing (VT)
Trial: 21793047
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy (CPT) in-person modality
Trial: 10967604
Drug: 73.5 mg
RxNorm normalized name: silymarin 73.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 73.5 mg RRR‐alpha‐tocopherol acetate
Trial: 8695075
Drug: Ketorolac 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 0.75 mg/kg
Trial: 20466223
Drug: Meperidine 1
RxNorm normalized name: meperidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine 1 mg/kg
Trial: 6434081
Drug: Vitamin D2
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin D2 25 micrograms daily
Trial: 6434081
Drug: Alfacalcidol 0.5
RxNorm normalized name: alfacalcidol 0.5 MCG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol 0.5 micrograms daily
Trial: 24872684
Drug: Whole-body vibration
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body vibration (WBV) at 30 Hz and 3.2 g for 3 months
Trial: 17688462
Drug: High-dose dopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dopamine precursors in Parkinson's disease
Trial: 12402427
Drug: Intraportal chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraportal chemotherapy with 10 mg/body of mitomycin and 500 mg/m2 of 5-FU for 7 days followed by oral 5-FU
Trial: 11219972
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 5-FU
Trial: 12402427
Drug: Intraportal chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraportal chemotherapy for stage III colorectal cancer
Trial: 12063371
Drug: Intranasal mupirocin
RxNorm normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal mupirocin
Trial: 2865422
Drug: Oral ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ketoconazole
Trial: 9620106
Drug: Antifungal prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antifungal prophylaxis
Trial: 2107237
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose rt-PA (2 mg/kg body weight over 3 h)
Trial: 2107237
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose rt-PA (1.25 mg/kg over 3 h)
Trial: 2107237
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose rt-PA (2 mg/kg)
Trial: 2107237
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose rt-PA (1.25 mg/kg)
Trial: 31767184
Drug: Fresh blastocysts
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh blastocysts without treatment (Group 5)
Trial: 28668998
Drug: Magnesium-Zinc-Calcium-Vitamin D
RxNorm normalized name: calcium carbonate / magnesium oxide / zinc oxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium-Zinc-Calcium-Vitamin D co-supplementation (100 mg magnesium, 4 mg zinc, 400 mg calcium, 200 IU vitamin D, twice a day for 12 weeks)
Trial: 28668998
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice a day for 12 weeks)
Trial: 20920179
Drug: Worsening of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Worsening of akathisia (measured by the Barnes Akathisia Scale) during the first two weeks of treatment
Trial: 20920179
Drug: Worsening of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Worsening of symptoms of depression/anxiety (subscale score on the Positive and Negative Syndrome Scale) during the first two weeks of treatment
Trial: 20920179
Drug: Lack of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lack of antipsychotic use in the prior year
Trial: 17256807
Drug: Omeprazole (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (after dose adjustment)
Trial: 12596444
Drug: OptiMAL test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OptiMAL test for Plasmodium falciparum (sequential design)
Trial: 12596444
Drug: OptiMAL test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OptiMAL test for Plasmodium vivax (sequential design)
Trial: 2761917
Drug: Intramuscular interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular interferon alpha‐2b (3 x 10(6) U (3 MU)/m2 daily for 3 weeks, total dose 63 MU/m2)
Trial: 2761917
Drug: Intramuscular interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular interferon alpha‐2b
Trial: 2761917
Drug: Subcutaneous interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous interferon alpha‐2b
Trial: 31264943
Drug: Donepezil (2.5‐10.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (2.5‐10.0 mg per day)
Trial: 10853843
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy followed by irradiation (CTRT)
Trial: 8222816
Drug: Antireflux therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antireflux therapy
Trial: 8222816
Drug: Distal esophageal
RxNorm normalized name: Cellspan Esophageal Implant
DrugBank: Cellspan Esophageal Implant (DB18688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distal esophageal infusion of 0.1 N HCl
Trial: 2419687
Drug: Mexiletine 200
RxNorm normalized name: mexiletine 200 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine 200 mg IMI
Trial: 2419687
Drug: Mexiletine 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine 300 mg IMI
Trial: 2419687
Drug: Mexiletine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine 400 mg IMI
Trial: 2419687
Drug: Mexiletine 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine 500 mg IMI
Trial: 27322164
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (FDC) TB drugs
Trial: 27322164
Drug: Loose formulation
RxNorm normalized name: loose wheat smut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loose formulation (LF) TB treatment regimens
Trial: 18598093
Drug: Sildenafil 100
RxNorm normalized name: sildenafil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 100 mg alone
Trial: 15992513
Drug: Plant sterol
RxNorm normalized name: plant sterol complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterol ester 1.6 g/day
Trial: 15992513
Drug: Plant stanol
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant stanol ester 1.6 g/day
Trial: 15992513
Drug: Plant stanol
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant stanol ester 2.6 g/day
Trial: 12074224
Drug: Rotary preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotary preparation with diamond burs
Trial: 12074224
Drug: Sonicflex 2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonicflex 2000 L/N (HS)
Trial: 2706044
Drug: Moderate freshwater
RxNorm normalized name: FRESHWATER DRUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate freshwater fish diet (3.7 fish meals per week, about 1 g of n‐3 fatty acids daily)
Trial: 790552
Drug: Ketoprofen (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen (200 mg daily)
Trial: 796938
Drug: Aspirin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (4 g daily)
Trial: 29846605
Drug: 14 day
RxNorm normalized name: Ponvory 14 Day Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 day sequential therapy
Trial: 27124695
Drug: Intensive glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glycemic control (IG, target 140 mg/dL)
Trial: 27124695
Drug: Moderate glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate glycemic control (MG, target 180 mg/dL)
Trial: 25412669
Drug: Preoperative electroacupuncture
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative electroacupuncture at PC6, ST36, and ST37 bilaterally with electrical stimulation twice a day for 20 min
Trial: 25412669
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (routine treatment without electroacupuncture)
Trial: 23138518
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (200 mg hydroxychloroquine sulfate)
Trial: 23138518
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (200 mg hydroxychloroquine sulfate)
Trial: 12121601
Drug: Twinrix vaccine
RxNorm normalized name: TWINRIX vaccine 1 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twinrix vaccine (combined hepatitis A and B vaccine) administered on a 0‐, 1‐ and 6‐month schedule
Trial: 8943591
Drug: Morphine via
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine via patient controlled analgesia and local cooling of the wound by an externally applied cooling pad
Trial: 6177371
Drug: Heparin-Dihydroergotamine (DHE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-Dihydroergotamine (DHE)
Trial: 17674518
Drug: Selenium enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium enriched food supplement based on spirulina
Trial: 10710009
Drug: Ferrum H
RxNorm normalized name: Ferrum
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrum H (5x2ml intramuscular injections)
Trial: 2264362
Drug: Parenteral immunization
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral immunization with 'Influmun' from SSW Dresden, GDR
Trial: 2264362
Drug: Oral immunization
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunization with an inactivated influenza vaccine using enteric-coated capsules
Trial: 7041579
Drug: Nylidrin HCl
RxNorm normalized name: nylidrin HCl
DrugBank: Nylidrin (DB06152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nylidrin HCl (3 mg)
Trial: 18040527
Drug: Colchicine and
RxNorm normalized name: colchicine and probenecid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine and vitamin E therapy
Trial: 9352981
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of streptokinase and alteplase
Trial: 9352981
Drug: Irrespective of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irrespective of treatment
Trial: 28835513
Drug: pembrolizumab (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pembrolizumab (2 mg/kg IV every 3 weeks)
Trial: 28835513
Drug: pembrolizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pembrolizumab (10 mg/kg IV every 3 weeks)
Trial: 28256066
Drug: docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: docetaxel (75 mg/m2 every 3 weeks)
Trial: 15610829
Drug: Naltrexone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone treatment (50 mg daily)
Trial: 15695979
Drug: Cooperative group
RxNorm normalized name: cloperastine
DrugBank: Cloperastine (DB09002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooperative group trials for Stage IB 2 disease treated with radiation therapy
Trial: 10629347
Drug: Glycine 0.5
RxNorm normalized name: GLYCINE 0.5 g in 100 g DENTAL PASTE, DENTIFRICE [CAREDO Treating Gingivitis Toothpastes 100g]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycine 0.5 g/day
Trial: 1353607
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg per day of didanosine
Trial: 1353607
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg per day of didanosine
Trial: 1353607
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg per day of zidovudine
Trial: 6375804
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg metronidazole three times daily for seven days
Trial: 6364329
Drug: 2000 mg
RxNorm normalized name: bran 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg metronidazole as a single dose
Trial: 6375804
Drug: 2000 mg
RxNorm normalized name: bran 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg metronidazole on days 1 and 2
Trial: 6375804
Drug: 2000 mg
RxNorm normalized name: bran 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg metronidazole on days 1 and 3
Trial: 8730975
Drug: Allopurinol 50
RxNorm normalized name: allopurinol 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol 50 mg
Trial: 30290598
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment and cognitive rehabilitation training
Trial: 26965760
Drug: Higher salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher salt intake group (>=10.0 g/day, n=362)
Trial: 20210592
Drug: Functional electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional electrical stimulation (FES) therapy
Trial: 10422040
Drug: Tibolone 2.5
RxNorm normalized name: tibolone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 2.5 mg/day for 28 days
Trial: 15823823
Drug: Sequential estrogen-progestogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential estrogen-progestogen therapy (0.625 mg CEE for 25 days + 5 mg MPA on days 16-25)
Trial: 15823823
Drug: Sequential estrogen-progestogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential estrogen-progestogen therapy
Trial: 11991622
Drug: rebamipide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rebamipide (300 mg daily for 12 months)
Trial: 9850405
Drug: Oral halofantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral halofantrine 8 mg/kg body weight every 6 h for 3 doses
Trial: 2809856
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 300 mg daily for 1 week, followed by 3.4 g eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for 4 weeks
Trial: 2809856
Drug: 3.4 g
RxNorm normalized name: psyllium 3.4 g oral wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.4 g daily of EPA and DHA for 4 weeks, followed by ASA 300 mg daily for 1 week
Trial: 25294250
Drug: Oritavancin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oritavancin (single intravenous 1200-mg dose)